Biotech Takes It on the Chin in May

PR Newswire (press release) - New York,NY,USA
... Index (-9.6%) Biogen Idec and Fumapharm AG announced positive results from a Phase II study designed to evaluate the efficacy and safety of BG-12, an oral ...

Biogen Idec Says BG-12 Meets Target In Phase II Study Of Relapsing ...
Trading Markets - Los Angeles,CA,USA
... Biogen Idec (BIIB | charts | news | PowerRating) said results from a Phase II study designed to evaluate the efficacy and safety of BG-12 achieved its primary ...

Biogen drug does well in human trial
Triangle Business Journal - Raleigh,NC,USA
Biotech giant Biogen Idec announced Tuesday that its multiple sclerosis drug BG-12 met its primary goals in a recent phase II human trial. ...

Oral Compound BG-12 Achieves Primary Endpoint in Phase II Study of ...
Genetic Engineering News - Larchmont,NY,USA
Biogen Idec (NASDAQ: BIIB) and Fumapharm AG announced positive results from a Phase II study designed to evaluate the efficacy and safety of BG-12, an oral ...

Encouraging phase II for Biogen Idec's multiple sclerosis drug
Pharmaceutical Business Review - USA
A phase II study, designed to evaluate Biogen Idec's investigational oral fumarate BG-12 in patients with relapsing-remitting multiple sclerosis, has yielded ...
See all stories on this topic

Zoek in het archief
Netherlands Corporate News (persbericht) - Netherlands
( BW)(BIOGEN-IDEC/FUMAPHARM)(BIIB) Oral Compound BG-12 Achieves Primary Endpoint in Phase II Study of Relapsing-Remitting Multiple Sclerosis; Treatment with BG ...